A Rutgers University expert who is leading a series of Remdesivir trials for people with COVID-19 is available to discuss the drug as a possible treatment as well as preliminary positive results from the trials.
“As seen in a news release from the NIH and as part of the ongoing international study with Gilead, our experience with the 90 patients enrolled in our clinical trial in New Jersey makes us optimistic about the drug’s ability to have a positive impact for patients with COVID 19, said Ronald G. Nahass, a clinical professor at Rutgers Robert Wood Johnson Medical School, president of ID Care and principal investigator for a series of Remdesivir trials for patients with COVID-19 in Central New Jersey. “We’re hoping the national analysis demonstrates that the drug is effective and safe, so the FDA can rapidly approve it and make it widely available through an emergency use authorization.”
Rutgers University–New Brunswick has broadcast-quality TV and radio studios available for remote live or taped interviews. For more information, contact Neal Buccino firstname.lastname@example.org
Rutgers Biomedical and Health Sciences (RBHS) takes an integrated approach to educating students, providing clinical care and conducting research, all with the goal of improving human health. Aligned with Rutgers University–New Brunswick, and collaborating university-wide, RBHS includes eight schools, a behavioral health network and four centers and institutes. RBHS offers an outstanding education in medicine, dentistry, pharmacy, public health, nursing, biomedical research and the full spectrum of allied health careers. RBHS clinical and academic facilities are located throughout the state.